Bank of Montreal Can decreased its holdings in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 31.5% in the 4th quarter, Holdings Channel reports. The firm owned 23,937 shares of the medical research company’s stock after selling 11,016 shares during the quarter. Bank of Montreal Can’s holdings in PRA Health Sciences were worth $2,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Magnetar Financial LLC bought a new stake in PRA Health Sciences during the third quarter valued at $5,010,000. Sei Investments Co. increased its stake in PRA Health Sciences by 8.5% during the third quarter. Sei Investments Co. now owns 15,899 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 1,245 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in PRA Health Sciences by 12.0% during the third quarter. Alyeska Investment Group L.P. now owns 463,941 shares of the medical research company’s stock valued at $35,338,000 after purchasing an additional 49,693 shares during the last quarter. Royal Bank of Canada increased its stake in PRA Health Sciences by 748.4% during the second quarter. Royal Bank of Canada now owns 6,626 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 5,845 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in shares of PRA Health Sciences by 3.9% during the third quarter. California Public Employees Retirement System now owns 83,425 shares of the medical research company’s stock worth $6,354,000 after acquiring an additional 3,125 shares during the last quarter. Hedge funds and other institutional investors own 97.39% of the company’s stock.

Several equities analysts have recently commented on PRAH shares. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Jefferies Group restated a “buy” rating and set a $95.00 price target on shares of PRA Health Sciences in a research report on Thursday, October 26th. Robert W. Baird set a $94.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, KeyCorp restated a “buy” rating and set a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Buy” and a consensus target price of $92.31.

In related news, insider David W. Dockhorn sold 72,850 shares of the company’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The disclosure for this sale can be found here. Insiders sold 217,815 shares of company stock valued at $19,690,710 in the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Shares of PRA Health Sciences Inc (PRAH) opened at $85.43 on Monday. The firm has a market cap of $5,410.00, a PE ratio of 47.99, a P/E/G ratio of 1.16 and a beta of 0.31. PRA Health Sciences Inc has a 1-year low of $57.72 and a 1-year high of $95.90. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2018/02/12/bank-of-montreal-can-sells-11016-shares-of-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.